Prelude Therapeutics Inc·4

Jan 7, 4:15 PM ET

Huang Jane 4

4 · Prelude Therapeutics Inc · Filed Jan 7, 2025

Insider Transaction Report

Form 4
Period: 2025-01-04
Huang Jane
President, CMO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-04+9,37572,716 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-01-04+9,37546,875 total
    Common Stock (9,375 underlying)
  • Tax Payment

    Common Stock

    2025-01-04$1.39/sh3,859$5,36468,857 total
Footnotes (3)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
  • [F2]Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
  • [F3]The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT